Tubulin-binding dibenz[c,e]oxepines. Part 2. 1 Structural variation and biological evaluation as tumour vasculature disrupting agents
dc.contributor.author | Rossington, S.B. | * |
dc.contributor.author | Hadfield, J.A. | * |
dc.contributor.author | Shnyder, Steven D. | * |
dc.contributor.author | Wallace, T.W. | * |
dc.contributor.author | Williams, K.J. | * |
dc.date.accessioned | 2017-02-01T11:45:01Z | |
dc.date.available | 2017-02-01T11:45:01Z | |
dc.date.issued | 2017-03-01 | |
dc.identifier.citation | Rossington SB, Hadfield JA, Shnyder SA et al (2017) Tubulin-binding dibenz[c,e]oxepines: Part 2. 1 Structural variation and biological evaluation as tumour vasculature disrupting agents. Bioorganic and Medicinal Chemistry. 25(5): 1630-1642. | en_US |
dc.identifier.uri | http://hdl.handle.net/10454/11235 | |
dc.description | Yes | en_US |
dc.description.abstract | 5,7-Dihydro-3,9,10,11-tetramethoxybenz[c,e]oxepin-4-ol 1, prepared from a dibenzyl ether precursor via Pd-catalysed intramolecular direct arylation, possesses broad-spectrum in vitro cytotoxicity towards various tumour cell lines, and induces vascular shutdown, necrosis and growth delay in tumour xenografts in mice at sub-toxic doses. The biological properties of 1 and related compounds can be attributed to their ability to inhibit microtubule assembly at the micromolar level, by binding reversibly to the same site of the tubulin αβ-heterodimer as colchicine 2 and the allocolchinol, N-acetylcolchinol 4. | en_US |
dc.language.iso | en | en_US |
dc.relation.isreferencedby | http://dx.doi.org/10.1016/j.bmc.2017.01.027 | en_US |
dc.rights | © 2017 Elsevier. Reproduced in accordance with the publisher's selfarchiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by-nc-nd/4.0/) | en_US |
dc.subject | Dibenz[c,e]oxepine; Iintramolecular direct arylation; Tubulin targeting; Tumour growth inhibition; Vascular shutdown; Colchicinoid | en_US |
dc.title | Tubulin-binding dibenz[c,e]oxepines. Part 2. 1 Structural variation and biological evaluation as tumour vasculature disrupting agents | en_US |
dc.status.refereed | Yes | en_US |
dc.date.Accepted | 2017-01-17 | |
dc.date.application | 2017-01-19 | |
dc.type | Article | en_US |
dc.type.version | Accepted Manuscript | en_US |
refterms.dateFOA | 2018-01-20T00:00:00Z |